anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Debates about the prospective clinical use of polygenic risk scores (PRS) have grown considerably in the last years. The potential benefits of PRS to improve patient care at individual and population levels have been extensively underlined. Nonetheless, the use of PRS in clinical contexts presents a number of unresolved ethical challenges and consequent normative gaps that hinder their optimal implementation. Here, we conducted a systematic review of reasons of the normative literature discussing ethical issues and moral arguments related to the use of PRS for the prevention and treatment of common complex diseases. In total, we have included and analyzed 34 records, spanning from 2013 to 2023. The findings have been organized in three major themes: in the first theme, we consider the potential harms of PRS to individuals and their kin. In the theme "Threats to health equity," we consider ethical concerns of social relevance, with a focus on justice issues. Finally, the theme "Towards best practices" collects a series of research priorities and provisional recommendations to be considered for an optimal clinical translation of PRS. We conclude that the use of PRS in clinical care reinvigorates old debates in matters of health justice; however, open questions, regarding best practices in clinical counseling, suggest that the ethical considerations applicable in monogenic settings will not be sufficient to face PRS emerging challenges.
<P>PROBLEM TO BE SOLVED: To provide a highly safe and naturally occurring antioxidizing substance having an excellent active oxygen scavenging ability.  <P>SOLUTION: It is shown for the first time that citrulline has an active oxygen scavenging ability. A new active oxygen scavenger comprising the citrulline as an active ingredient has the excellent active oxygen scavenging ability and is characterized as being highly safe. Thereby, a therapeutic agent or a prophylactic agent for diseases caused by active oxygen injury and comprising the citrulline as an active ingredient and an antioxidizing food additive comprising the citrulline as the active ingredient are provided. Furthermore, the citrulline has actions of protecting a DNA from the active oxygen injury, and a DNA cleavage preventive agent comprising the citrulline as the active ingredient is provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants randomized to the sham condition will complete a computerized sham ICT training at home during the first 4 weeks of treatment and sham ICT "boosters" following their treatment sessions during weeks 5-12. The shame will contain the same proportion of food as non-food but no inhibitory training component.
FIELD: medicine. ^ SUBSTANCE: application of a fluridon herbicide (1-methyl-5 (,,-trifluoro-m-tolyl)-3-phenylpyridinon-4) of the structural formula (I) as an agent for treatment of oncologic diseases with a disposable dosage from 0.1 mg to 5 g on reception to 3 times a day is offered. It is possible to take fluridon in the form of a dry powder or as an aqueous solution in rectal, intravenous or intraperitoneal manner, in the form of ointment, candles, or inhalant. Efficiency of treatment of oncologic diseases is shown: adenocarcinoma, melanoma with metastasises, carcinoma, non-Hodgkin's lymphoma, liver cancer, glioblastoma, and sarcoma. ^ EFFECT: development of a substance which suppresses proliferation of cancer cells more effectively than doxorubicine, does not cause by-effects in patients at its use. ^ 8 cl, 5 tbl, 13 ex
In this crossover study, participants will be randomized to either a low or standard carbohydrate for 2 weeks. Participants in the low carbohydrate group will limit carbohydrate intake to 15% of total daily calories.
1. Use of a bacterial combination composition comprising as bacterial strains: (a) Streptococcus thermophilus in admixture with (b) at least one bacterial strain selected from the group consisting of Lactobacillus brevis, Lactobacillus acidophilus, Lactobacillus plantarurm, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium brave or mixtures thereof, for preparing a dietary, pharmaceutical or veterinary composition for the prevention and/or treatment of hyperoxaluria and the disorders associated therewith. 2. The use of Claim 1, wherein the strain of Lactobacillus brevis is the strain of Lactobacillus brevis DSM 11988. 3. The use of claim 1, wherein the ratio of the concentrations of Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve in the mixture, expressed in CFU/g of composition, are 1:1:1. 4. The use of claims 1-2, wherein the ratio of the concentrations of Streptococcus thermophilus and the Lactobacillus strain, expressed in CFU/g of composition, is from 1000:1 to 1:1000. 5. The use of claim 1, wherein the ratio of the concentrations of Streptococcus thermophilus and the Bifidobacterium strain, expressed in CFU/g of composition, is from 1000:1 to 1:1000. 6. A method for the prevention and/or treatment of hyperoxaluria and the disorders associated therewith which comprises administering to an animal in need thereof from 0.5 to 4 g/die of a bacterial combination composition comprising: (a) Streptococcus thermophilus in admixture with (b) at least one bacterial strain selected from the group consisting of Lactobacillus brevis, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium infantis, Bifidobacterium longum and Bifidobacterium breve or mixtures thereof.
To provide novel radical polymerizable silane coupling agents having a cyclic compound skeleton, and medical/dental curable compounds containing the same.SOLUTION: Disclosed is a silane coupling agent having a urethane bond and a polymerizable group represented by the following formula, in which A is HC=CH-, HC=C(CH)-, etc.; B is -C(O)-O-, etc.; Rand Rare alkylene of C2-C100; Z is a group comprising one or more benzene rings or cyclohexane rings; Ris methyl, ethyl, etc.; Ris alkyl or phenyl of C1-C16 or halogen atom and when n is 0, at least one or more halogen atoms are bonded to Si, a is an integer of 1-6 and n is an integer of 0-3. Also disclosed is an inorganic filler having a surface treated with the silane coupling agent. Further disclosed is a medical/dental curable composition comprising the inorganic filler and a radical polymerizable monomer and at least one of a polymerization initiator and a polymerization accelerator.SELECTED DRAWING: None
Spider veins on the lower limbs are very common and have been reported to be presented in 41% of women over 50 years old. Sclerotherapy as a traditional treatment for spider veins has a low cost, though it may have adverse sequelae. Lasers have shown fewer but still substantial complications as well.1 Spider veins are small superficial veins that widen and become visible, often on the legs and most cutaneous spider veins are abnormalities of the horizontal vascular skin plexus or capillary loops.2 Spider leg veins are composed of a feeder vessel and ectatic venous sprouts in the reticular dermis. Their depth is between 180 µm and 1 mm in the skin.3 Spider veins may have a diameter that reaches several millimetres and can be blue, purple or red and may appear in the form of thin lines, webs or branches.4 There is a scarce available data from literature about the role of micro-cauterization in the treatment of spider veins. The micro-cauterization is an alternative in management of spider veins that delivered via Mole Freckle Pen German Technology.4 Cautery is a safe and effective tool for the treatment of superficial and small skin lesions. It is simple, cheap, and requires minimal training and the results are usually satisfactory Technology Specifications with insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5 The current study aims to evaluate the role for micro-cauterization in the treatment and disappearance of spider leg veins.
BACKGROUND: Colon cancer (CC) is a malignancy associated with significant morbidity and mortality within the gastrointestinal tract. Recurrence and metastasis are the main factors affecting the prognosis of CC patients undergoing radical surgery; consequently, we attempted to determine the impact of immunity-related genes.
RESULT: We constructed a CC risk model based on ZG16, MPC1, RBM47, SMOX, CPM and DNASE1L3. Consistently, we found that a significant association was found between the expression of most characteristic genes and tumor mutation burden (TMB), microsatellite instability (MSI) and neoantigen (NEO). Additionally, a notable decrease in RBM47 expression was observed in CC tissues compared with that in normal tissues. Moreover, RBM47 expression was correlated with clinicopathological characteristics and improved disease-free survival (DFS) and overall survival (OS) among patients with CC. Lastly, immunohistochemistry and co-immunofluorescence staining revealed a clear positive correlation between RBM47 and CXCL13 in mature tertiary lymphoid structures (TLS) region.
CONCLUSION: We conclude that RBM47 was identified as a prognostic-related gene, which was of great significance to the prognosis evaluation of patients with CC and was correlated with CXCL13 in the TLS region.
Forearm fractures are among the most frequent reasons for adults to visit the emergency department. These fractures cause significant pain both due to the fracture itself and during the reduction process. Pain management in emergency departments (ED) is crucial. Therefore, multimodal approaches are available to reduce or eliminate pain during the reduction process. The aim of this study is to evaluate the success and pain palliation of the reduction process with procedural sedation-analgesia (PSA) and with reduction under ultrasound (US)-guided infraclavicular nerve block (ICB) in patients with forearm fractures. The secondary aim is to compare patient comfort, physician comfort, side effects, length of stay in the emergency department, and the need for painkillers after discharge between these two procedures, and to identify the most suitable method. This study aims to contribute to practical applications in order to provide optimal pain control in patients with forearm fractures in emergency departments.

Patients' pain levels at arrival, pre-reduction procedure, and post-reduction procedure will be recorded using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).The success of the reduction procedure, whether further reduction attempts were necessary, and findings from post-reduction control X-rays (radial height, radial tilt, and volar tilt) will be noted and evaluated by orthopedic physicians.
The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutci-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic.
Participants will engage in a 5-session protocol, to be delivered in an individual therapy setting, via telehealth or in-person. The program will integrate aspects of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy.
Cervical Mobilization program, cervical mobilization techniques were applied to the patients for 30 minutes in addition to the traditional program. Cervical mobilization includes suboccipital relaxing techniques, myofascial muscle relaxing techniques for Levator scapula, trapezius, scalenes muscles. These techniques were applied bilaterally.
Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
In the control group, patients will be managed intraoperatively at the discretion of the attending anesthesiologists, in accordance with their institutional protocols (i.e. fluids and/or vasoactive agents are given to maintain mean arterial pressure ≥ 65 mmHg).
Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
Patients receive axatilimab IV over 30 minutes on days 1 and 15 and azacitidine IV over 10-40 minutes or SC on days 1-7 of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve PR or better may continue for up to 24 total cycles. Patients who achieve less than PR receive 2 additional cycles and, if PR or better is achieved, may complete up to 24 total cycles. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.
The present invention provides a classification and a prescription for five symptoms of chronic pharyngitis for the technical field of medicines. The present invention is characterized in that five symptoms of pharyngitis are established, and a special prescription and a special medicine are provided for each symptom, namely, a residual evil stagnating type, an anocelia deficiency type, an acute and chronic esophagitis type, a reddish swelling and pain type and a yin-deficiency qi-depression type; different treating prescriptions comprising No. 1 pill for treating pharyngitis, No. 2 pill for treating pharyngitis, No. 3 pill for treating pharyngitis, No. 4 pill for treating pharyngitis and No. 5 pill for treating pharyngitis are arranged aiming at different symptoms. Compared with the existing traditional Chinese medicine for treating chronic pharyngitis, the present invention has the advantages of differentiation of symptoms and signs for classification of syndrome, treatment of both manifestation and root cause of disease, easy eradication, immune function enhancement after treatment, function adjustment of the whole body, health status realization of calm yin and sound yang, no toxic or side effect, superiority to antibiotic therapy and domestic blank filling.
Ecological Momentary Assessment (EMA; Metricwire). Participants randomized to this group will be sent prompts through the EMA app to complete brief EMA survey at 6 random times per day. Participants randomized to this group will earn a fixed bonus/incentive based on completion of the EMA surveys (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.
PURPOSE: A composition and a food composition containing Ecklonia stolonifera extract are provided to reduce serum lipid content and LDL(low-density lipoprotein) cholesterol amount and to prevent or treat cardiovascular diseases. CONSTITUTION: A composition for preventing or treating cardiovascular diseases contains Ecklonia stolonifera extract as an active ingredient. The extract is prepared using alcohol of 1-5 carbon atoms, water, or a mixture thereof. The cardiovascular diseases are dyslipidemia, hyperlipidemia, arteriosclerosis, coronary artery disease, hypertension, menopausal dyslipidemia, or menopausal hypertension. A composition for preventing or treating menopausal dyslipidemia, or menopausal hypertension contains the Ecklonia stolonifera ethanol solution extract as an active ingredient. The composition also contains 0.001-99.99 wt% of Codonopsis lanceolata extract.
Compositions and methods for selectively inhibiting mTOR and/or increasing autophagy in a tissue of a subject have been developed for the treatment of cancer. Caged mTOR inhibitor prodrugs comprising a photocleavable protecting group are provided for use in selective chemotherapy by a photochemotherapeutic system. Pharmaceutical compositions of mTOR inhibitors are provided that are deactivated (caged) with a photo-removable protecting group to controllably block the inhibitory activity of the inhibitor. The photoremovable group is cleavable upon exposure to light irradiation, releasing an active inhibitor of mTOR signaling and autophagy at the site of irradiation. An exemplary caged mTOR inhibitor prodrug is a caged OSI-027 prodrug (ciosi-027) having a DEACM moiety bound thereto. cOSI-027 is activated in the tumour region by exposure to light at 420nm to remove the DEACM protecting group.
Clostridium septicum is one of the major causative agents of clostridial dermatitis (CD), an emerging disease of turkeys, characterized by sudden deaths and necrotic dermatitis. Despite its economic burden on the poultry industry, the immunopathological changes and pathogen-specific immune responses are poorly characterized. Here, we used three strains of C. septicum, namely Str. A1, Str. B1 and Str. C1, isolated from CD field outbreaks, to experimentally infect turkeys to evaluate local (skin and muscle) and systemic (spleen) pathological and immunological responses. Results showed that while all three strains produced an acute disease, Str. A1 and B1 caused significantly higher mortality when compared to Str. C1. Gross and histopathology evaluation showed that birds infected with Str. A1 and B1 had severe inflammatory, edematous, granulomatous and necrotic lesions in the skin, muscle and spleen, while these lesions produced by Str. C1 were relatively less severe and mostly confined to skin and/or muscle. Immune gene expression in these tissues showed that Str. B1-infected birds had significantly higher expression of interleukin (IL)-1β, IL-6 and interferon (IFN)γ genes compared to uninfected control, suggesting a robust inflammatory response both locally as well as systemically. The transcription of IL-1β and IFNγ in the muscle or spleen of Str. A1-infected birds and IL-1β in the skin of Str. C1-infected group was also significantly higher than control. Additionally, Str. A1 or B1-infected groups also had significantly higher IL-4 transcription in these tissues, while birds infected with all three strains developed C. septicum-specific serum antibodies. Furthermore, splenic cellular immunophenotyping in the infected turkeys showed a marked reduction in CD4+ cells. Collectively, it can be inferred that host responses against C. septicum involve an acute inflammatory response along with antibody production and that the disease severity seem to depend on the strain of C. septicum involved in CD in turkeys.
The present invention relates to a urinary function enhancing composition using oriental medicine ingredients and a preparing method thereof. The present invention can be effective in preventing and treating prostate disorders and acute and chronic prostatitis in particular. The composition can also be used to treat sexual function syndromes as well as various types of urinary syndromes including residual urine, frequent urine, urinary urge, weak urine stream, oposiuria, nighttime urine, dense urine, and dysuria. The composition includes extracts of mixed oriental medicine ingredients including Lonicera japonica Thunberg, Citrus unshiu Markovich, Astragalus membranaceus Bunge, Trichosanthes kirilowii, Saposhnikovia divaricata Schiskin, Angelica gigas Nakai, Cnidium officinale Makino, Angelica dahurica Bentham, Platycodon grandiflorum A. De Candolle, Magnolia officinalis Rehder et Wilson, Gleditsia sinensis Lamark, Ulmus davidiana for. suberosa, Rubus coreanus Miquel, and Epimedium brevicornum Maximowicz. The method includes the following steps: (a) mixing the oriental medicine ingredients including 1-20 parts by weight of Lonicera japonica Thunberg, 1-10 parts by weight of Citrus unshiu Markovich, 1-10 parts by weight of Astragalus membranaceus Bunge, 1-10 parts by weight of Trichosanthes kirilowii, 1-10 parts by weight of Saposhnikovia divaricata Schischkin, 1-10 parts by weight of Angelica gigas Nakai, 1-10 parts by weight of Cnidium officinale Makino, 1-10 parts by weight of Angelica dahurica Bentham, 1-10 parts by weight of Platycodon grandiflorum A. De Candolle, 1-10 parts by weight of Magnolia officinalis Rehder et Wilson, 1-10 parts by weight of Gleditsia sinensis Lamark, 1-40 parts by weight of Ulmus davidiana for. suberosa, 1-10 parts by weight of Rubus coreanus Miquel, and 1-10 parts by weight of Epimedium brevicornum Maximowicz; (b) adding the mixture in a nonwoven fabric bag and putting the bag in a medicine boiling container storing water to boil down the mixture in a pressureless circulation state; and (c) filtering the boiled-down medicine.
People with chronic pain tend to interpret ambiguous information as health-related, more so than people without. In this study, we aimed to investigate whether people with rheumatoid arthritis (RA) exhibit this interpretation bias and whether it is associated with fear of disease progression (FoP). The interpretation biases of people with RA (n = 164) were compared with an age- and gender-matched control group. We hypothesized that (1) people with RA would have larger interpretation biases than people without; (2) those who scored in the clinical range for FoP would have larger interpretation bias than those who did not; (3) interpretation bias would moderate the relationship between pain severity and FoP; and (4) interpretation bias would explain variance in FoP above and beyond other established predictors. Our results confirmed that people with RA were more likely to interpret ambiguous information as health-related compared with people without RA. This effect was more pronounced for the RA subgroup with clinically significant FoP than those scoring in the normal range. We did not find evidence to suggest interpretation bias moderated the relationship between pain and FoP or that FoP added to the variance of other known predictors. Our results indicate that interpretation bias is common amongst people with RA and is associated with FoP. Further research is required to illuminate the exact nature of this relationship.
The clinical trial was designed randomized and blind. Participants included up to 900 persons. The clinical trial had two stages: the first stage selected 60 subjects to be administered test vaccine for preliminary safety study; 840 subjects were selected at the second stage for the observation of the safety and immunogenicity against the test vaccine administered on large population on the basis of the first stage. There were 560 subjects and 280 subjects in the test group and control group respectively.

Venous blood from subjects was collected before immunization and 4 weeks after the whole immunization for the analysis of the immunogenicity. The information about adverse reactions/time was reported to the SFDA every month during the trial under the status of blinding. Unblinding was conducted after the subject follow-up and observation.